Visual loss with erectile dysfunction medications

CMAJ. 2006 Aug 15;175(4):355. doi: 10.1503/cmaj.060935. Epub 2006 Jul 26.
No abstract available

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
  • Atherosclerosis / complications
  • Carbolines / adverse effects
  • Carbolines / therapeutic use
  • Erectile Dysfunction / drug therapy
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use
  • Male
  • Optic Neuropathy, Ischemic / chemically induced*
  • Phosphodiesterase Inhibitors / adverse effects*
  • Phosphodiesterase Inhibitors / therapeutic use
  • Piperazines / adverse effects
  • Piperazines / therapeutic use
  • Purines
  • Risk Factors
  • Sildenafil Citrate
  • Sulfones / adverse effects
  • Sulfones / therapeutic use
  • Tadalafil
  • Triazines / adverse effects
  • Triazines / therapeutic use
  • Vardenafil Dihydrochloride
  • Vision Disorders / chemically induced*

Substances

  • Carbolines
  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • Tadalafil
  • Sildenafil Citrate
  • 3',5'-Cyclic-GMP Phosphodiesterases